MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics VANCOUVER, BC, Nov. 18, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing…


Previous articleEyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and Joe Moore
Next articleAlgernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study